HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q4 2016 13F Holders as of 31 Dec 2016

Type / Class
Equity / COM
Total 13F shares
2,887,834
Share change
-450,350
Total reported value
$6,469,840
Price per share
$2.24
Number of holders
12
Value change
-$1,022,225
Number of buys
5
Number of sells
10

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q4 2016

As of 31 Dec 2016, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 12 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,887,834 shares. The largest 10 holders included Novo A/S, FMR LLC, PUTNAM INVESTMENTS LLC, Cormorant Asset Management, LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, SONORA INVESTMENT MANAGEMENT, LLC, Ironwood Financial, llc, and BlackRock Fund Advisors. This page lists 12 institutional shareholders reporting positions in this security for the Q4 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.